Health. Liver risk: a new treatment for menopause under close surveillance

Available in France since April 8, 2025, Veoza (fezolintant) represents a breakthrough in the treatment of moderate to severe vasomotor symptoms of menopause. Unlike traditional hormone treatments, this medication acts directly on the temperature control center in the brain.

Liver risks that require close monitoring

However, the French National Agency for the Safety of Medicines (ANSM) has just issued a serious warning regarding this treatment. Analyses have identified rare but serious cases of liver damage. These effects can manifest as:

• a significant elevation of liver enzymes;
• symptoms such as fatigue, itching, jaundice, dark urine, loss of appetite or abdominal pain.

In a letter addressed to health professionals (general practitioners, gynecologists, hepato-gastroenterologists, pharmacy professionals), the ANSM recommends several precautionary measures, such as:

• a complete liver assessment is mandatory before any prescription;
• monthly monitoring of liver function during the first three months of treatment;
• immediate discontinuation of Veoza in the event of significant liver test abnormalities.

As for patients, they should be particularly attentive to signs of liver damage and consult a doctor immediately if symptoms appear.